DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO

April 14, 2024 11:15 PM PDT | By Cision

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO — Image source: Kalkine Media

Recent News

Personal Practitioners Az Announces Use Of Objective Adhd Testing Tech...

Donald Trump: The Whole Truth And Nothing But The Truth Revealed In Ne...

My 3M stock price forecast was correct: now what?

Short USD/CHF: market trend indicates the price is likely to drop furt...

SINGAPORE, April 15, 2024 /PRNewswire/ -- Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @ South San Francisco^[1] from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships and networks within the pharma and life science sector. Respiree was formerly a company at JLABS in Singapore.

With a physical presence to the US, the Respiree team will focus on utilizing the iRIS One decentralized clinical trials platform to help pharma companies in the US and broader global economies to optimize drug trials, discover newer lung and cardiac digital biomarkers and to aggregate broader and deeper real-world datasets. Respiree's team also aims to extend the development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

"We are very proud and excited to be continuing our JLABS journey, first as alumni of JLABS @ Shanghai, then JLABS Singapore and now to JLABS @ South San Francisco. We hope to work more closely within the life science and the pharmaceutical sector to enhance the iRIS One clinical trials platform. With our physical presence in the US, we hope to position ourselves to accelerate the development of our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster," said Respiree's CEO and Founder Dr Gurpreet Singh.

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023. It has signed several commercial agreements with multi-national companies to assist in their go-to-market penetration.

[1] Johnson & Johnson Innovation

About Respiree

Respiree is a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. Respiree is deployed internationally. Respiree's iRIS One clinical trials platform is CE marked, approved for use in Australia by the Therapeutics Goods Administration and received 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.